Pre-existing minor variants with NS5A L31M/V-Y93H double substitution are closely linked to virologic failure with asunaprevir plus daclatasvir treatment for genotype 1b hepatitis C virus infection.
Naoki MorishitaRyotaro SakamoriTomomi YamadaYugo KaiYuki TahataAyako UrabeRyoko YamadaTakahiro KodamaHayato HikitaYoshinori DoiShinji TamuraHideki HagiwaraYasuharu ImaiSadaharu IioTomohide TatsumiTetsuo TakeharaPublished in: PloS one (2020)
NS5A L31 and Y93 substitutions were detected in tandem by the deep sequencing methods in several genotype 1 patients, who may be more resistant to DAA treatment containing an NS5A inhibitor.